InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.13
(
1.07%
)
US TECH 100
18,744.80
(
0.00%
)
Dow Jones
40,861.71
(
0.31%
)
Brent Oil
71.46
(
1.33%
)
Bitcoin
58,031.71
(
1.20%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12532
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: PennyMann post# 40714

Saturday, 12/07/2013 9:44:14 AM

Saturday, December 07, 2013 9:44:14 AM

Post# of 80490
Elevated SAEs also found by other investigators: A study from French investigators (Nicolini et al., 2013 ASH meeting abstract #4020) found that in a cohort of 19 CML patients on Iclusig, 42% experienced CV events after a median of 8.5 months on drug, strikingly worse than a historical cohort of nilotinib-treated patients.
Source: Oppenheimer/Ferreiro, December 6, 2013

How did the Mot Fools miss that?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up